We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ENVX:NASDAQEnovix Corporation Analysis

Data as of 2026-09-09 - not real-time

$3.16

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Enovix Corporation trades at $3.16, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. Across the trailing 30 sessions it lost 20.4%. Momentum indicators put RSI at 36.6 (approaching oversold) with MACD reading bullish. Recent trading has carved out support near $3.06 and resistance around $5.03.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 259.2% above today's level. Revenue is growing at 20.8%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 105.9%, a beta of 3.76 and a maximum drawdown of 76.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
Near-term and long-term part ways here — sell short-term against hold longer out, with 3/10 conviction on the long call.

Top Market Events

Enovix Corporation ENVX delivered earnings and revenue surprises of +7.Second Quarter Revenue of $9.0 Million, Up 21% Year-over-Year, at High End of Guidance; First Half 2026 Revenue of...Enovix Corporation ENVX might move higher on growing optimism about its earnings prospects, which is reflected by its...

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 6.12
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 6.12
  • Analyst targets imply +259.2% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • Analyst targets imply +259.2% versus the current price
  • Negative return on equity of -81.3%
  • Revenue growth of +20.8%

Key Metrics & Analysis

Financial Health

Revenue Growth20.80%
P/E Ratio-5.0
ROE-81.28%
ROA-17.55%
Debt/Equity255.54
P/B Ratio3.2
Op. Cash Flow$-107378000
Free Cash Flow$-69503624
Industry P/E27.9

Technical Analysis

TrendBearish
RSI36.6
Support$3.06
Resistance$5.03
MA 20$3.54
MA 50$4.25
MA 200$6.12
MACDBullish
VolumeDecreasing
Fear & Greed Index92.04

Valuation

Target Price$11.35
Upside/Downside259.18%
GradeFair
TypeGrowth

Risk Assessment

Beta3.76
Volatility105.89%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.